The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs

Breast Cancer Research and Treatment

Volumn 126, Issue 1, 2011, Pages 203-209

  Atipairin, Apichart ^a   Canyuk, Bhutorn ^a   Ratanaphan, Adisorn ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

BARD1; BRCA1; Cancer therapy; Platinum drugs; Ubiquitin ligase

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PLATINUM; TRANSPLATIN;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER SURVIVAL; CHELATION; DNA REPAIR; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HYDROLYSIS; MULTIPLE CYCLE TREATMENT; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TREATMENT RESPONSE; UBIQUITINATION;

EID: 85027948794     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1182-7     Document Type: Article

References (36)

1. MSY Huen MH Shirley J Chen 2010 BRCA1 and its toolbox for the maintenance of genome integrity Nat Rev Mol Cell Biol 11 138 148 10.1038/nrm2831 1:CAS:528:DC%2BD1MXhsF2hs7fF 10.1038/nrm2831 20029420
2. PJ O'Donovan DM Livingston 2010 BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair Carcinogenesis 31 961 967 10.1093/carcin/bgq069 10.1093/carcin/bgq069 20400477
3. PS Brzovic P Rajagopal DW Hoyt MC King RE Klevit 2001 Structure of a BRCA1-BARD1 heterodimeric RING-RING complex Nat Struct Biol 8 833 837 10.1038/nsb1001-833 1:CAS:528:DC%2BD3MXnsVent70%3D 10.1038/nsb1001-833 11573085 (Pubitemid 32923599)
4. LC Wu ZW Wang JT Tsan MA Spillman A Phung XL Xu MCW Yang LY Hwang AM Bowcock R Baer 1996 Identification of a RING protein that can interact in vivo with the BRCA1 gene product Nat Genet 14 430 440 10.1038/ng1296-430 1:CAS:528:DyaK28XntlGgsbg%3D 10.1038/ng1296-430 8944023 (Pubitemid 26414587)
5. R Hashizume M Fukuda I Maeda H Nishikawa D Oyake Y Yabuki H Ogata T Ohta 2001 The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation J Biol Chem 276 14537 14540 10.1074/jbc. C000881200 1:CAS:528:DC%2BD3MXjs1Okt7g%3D 10.1074/jbc.C000881200 11278247 (Pubitemid 37373320)
6. Y Xia GM Pao H-W Chen IM Verma T Hunter 2003 Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein J Biol Chem 278 5255 5263 10.1074/jbc.M204591200 1:CAS:528:DC%2BD3sXhtVKltbs%3D 10.1074/jbc.M204591200 12431996 (Pubitemid 36801039)
7. S Bergink S Jentsch 2009 Principles of ubiquitin and SUMO modifications in DNA repair Nature 458 461 467 10.1038/nature07963 1:CAS:528: DC%2BD1MXjs1KltLY%3D 10.1038/nature07963 19325626
8. F Wu-Baer T Ludwig R Baer 2010 The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function Mol Cell Biol 30 2787 2798 10.1128/MCB.01056-09 1:CAS:528: DC%2BC3cXnsFKgs74%3D 10.1128/MCB.01056-09 20351172
9. DL Mallery CJ Vandenberg K Hiom 2002 Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains EMBO J 21 6755 6762 10.1093/emboj/cdf691 1:CAS:528:DC%2BD38XpslOgs7Y%3D 10.1093/emboj/cdf691 12485996 (Pubitemid 36014547)
10. LM Starita AA Horwitz MC Keogh C Ishioka JD Parvin N Chiba 2005 BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II J Biol Chem 280 24498 24505 10.1074/jbc.M414020200 1:CAS:528:DC%2BD2MXlsFyrur0%3D 10.1074/jbc. M414020200 15886201 (Pubitemid 40934535)
11. CM Eakin MJ MacCoss GL Finney RE Klevit 2007 Estrogen receptor α is a putative substrate of the BRCA1 ubiquitin ligase Proc Natl Acad Sci USA 104 5794 5799 10.1073/pnas.0610887104 1:CAS:528:DC%2BD2sXkt1Kgtr8%3D 10.1073/pnas.0610887104 17392432 (Pubitemid 47175613)
12. JR Morris 2010 More modifiers move on DNA damage Cancer Res 70 3861 3862 10.1158/0008-5472.CAN-10-0468 1:CAS:528:DC%2BC3cXlvFyrt7Y%3D 10.1158/0008-5472.CAN-10-0468 20406985
13. JR Morris C Boutell M Keppler R Densham D Weekes A Alamshah L Butler Y Galanty L Pangon T Kiuchi T Ng E Solomon 2009 The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress Nature 462 886 890 10.1038/nature08593 1:CAS:528:DC%2BD1MXhsFOhtLnL 10.1038/nature08593 20016594
14. DJ Ransburgh N Chiba C Ishioka AE Toland JD Parvin 2010 Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination Cancer Res 70 988 995 10.1158/0008-5472.CAN-09-2850 1:CAS:528:DC%2BC3cXht12qs74%3D 10.1158/0008-5472.CAN-09-2850 20103620
15. L Wei L Lan Z Hong A Yasui C Ishioka N Chiba 2008 Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80 Mol Cell Biol 28 7380 7393 10.1128/MCB.01075-08 1:CAS:528:DC%2BD1cXhsV2mtLnN 10.1128/MCB.01075-08 18936166
16. H Ruffner CAP Joazeiro D Hemmati T Hunter IM Verma 2001 Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity Proc Natl Acad Sci USA 98 5134 5139 10.1073/pnas.081068398 1:CAS:528: DC%2BD3MXjt1Ons7s%3D 10.1073/pnas.081068398 11320250 (Pubitemid 32397095)
17. Amir E, Seruga B, Serrano R, Ocana A (2010) Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev. doi: 10.1016/j.ctrv.2010.03.006
18. P Tassone MTD Martino M Ventura A Pietragalla I Cucinotto T Calimeri A Bulotta P Neri M Caraglia P Tagliaferri 2009 Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo Cancer Biol Ther 8 648 653 10.4161/cbt.8.7.7968 1:CAS:528: DC%2BD1MXotFSjsb0%3D 19333003
19. T Byrski T Huzarski R Dent J Gronwald D Zuziak C Cybulski J Kladny B Gorski J Lubinski SA Narod 2009 Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients Breast Cancer Res Treat 115 359 363 10.1007/s10549-008-0128-9 1:CAS:528:DC%2BD1MXmsVGjsrs%3D 10.1007/s10549-008- 0128-9 18649131
20. M Price ANA Monteiro 2010 Fine tuning chemotherapy to match BRCA1 status Biochem Pharmacol 80 647 653 10.1016/j.bcp.2010.05.015 1:CAS:528: DC%2BC3cXosV2is7k%3D 10.1016/j.bcp.2010.05.015 20510205
21. Y Sun 2006 E3 ubiquitin ligases as cancer targets and biomarkers Neoplasia 8 645 654 10.1593/neo.06376 1:CAS:528:DC%2BD28XhtVGltbjE 10.1593/neo.06376 16925947 (Pubitemid 44379791)
22. D Hoeller I Dikic 2009 Targeting the ubiquitin system in cancer therapy Nature 458 438 444 10.1038/nature07960 1:CAS:528:DC%2BD1MXjs1KltLk%3D 10.1038/nature07960 19325623
23. A Atipairin C Canyuk A Ratanaphan 2010 Cisplatin affects the conformation of apo-form, not holo-form, of BRCA1 RING finger domain and confers thermal stability Chem Biodivers 7 1949 1967 10.1002/cbdv.200900308 1:CAS:528: DC%2BC3cXhtVKjsbbM 10.1002/cbdv.200900308 20730959
24. PS Brzovic JR Keeffe H Nishikawa K Miyamoto D Fox III M Fukuda T Ohta R Klevit 2003 Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex Proc Natl Acad Sci USA 100 5646 5651 10.1073/pnas.0836054100 1:CAS:528:DC%2BD3sXjvFOmu7s%3D 10.1073/pnas.0836054100 12732733 (Pubitemid 36576862)
25. Z Wu Q Liu X Liang X Yang N Wang X Wang H Sun Y Lu Z Guo 2009 Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20 mer peptide corresponding to the N-terminal domain of human copper transporter 1 J Biol Inorg Chem 14 1313 1323 10.1007/s00775-009-0576-7 1:CAS:528:DC%2BD1MXpsF2itL8%3D 10.1007/s00775-009-0576-7 19669174
26. 2(CBDCA-O)(5'-GMP-N7)] in solution Inorg Chem 32 1333 1340 10.1021/ic00060a005 1:CAS:528:DyaK3sXhslKrs7w%3D 10.1021/ic00060a005
27. MS Davies SJ Berners-Price TW Hambley 2000 Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA Inorg Chem 39 5603 5613 10.1021/ic000847w 1:CAS:528:DC%2BD3cXotVyisLg%3D 10.1021/ic000847w 11151361 (Pubitemid 32065704)
28. L Trynda-Lemiesz H Kozøowski BK Keppler 1999 Effect of cis-, trans diamminedichloroplatinum(II) and DBP on human serum albumin J Inorg Biochem 77 141 146 10.1016/S0162-0134(99)00183-X 1:CAS:528:DC%2BD3cXnt1Oqtw%3D%3D 10.1016/S0162-0134(99)00183-X 10643655 (Pubitemid 30047063)
29. E Jerremalm P Videhult G Alvelius WJ Griffiths T Bergman S Eksborg H Ehrsson 2002 Alkaline hydrolysis of oxaliplatin-isolation and identification of the oxalato monodentate intermediate J Pharm Sci 91 2116 2121 10.1002/jps.10201 1:CAS:528:DC%2BD38XntlCqt7s%3D 10.1002/jps.10201 12226839
30. A Casini C Gabbiani E Michelucci G Pieraccini G Moneti PJ Dyson L Messori 2009 Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound J Biol Inorg Chem 14 761 770 10.1007/s00775-009-0489-5 1:CAS:528:DC%2BD1MXjtFOntLw%3D 10.1007/s00775-009-0489-5 19288144
31. M Groessl YO Tsybin CG Hartinger BK Keppler PJ Dyson 2010 Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterized by electrospray ionisation mass spectrometry J Biol Inorg Chem 15 677 688 10.1007/s00775-010-0635-0 1:CAS:528: DC%2BC3cXivV2rt74%3D 10.1007/s00775-010-0635-0 20213306
32. DP Silver AL Richardson AC Eklund ZC Wang Z Szallasi O Li N Juul C-O Leong D Calogrias A Buraimoh A Fatima RS Gelman PD Ryan NM Tung AD Nicolo S Ganesan A Miron C Colin DC Sgroi LW Ellisen EP Winer JE Garber 2010 Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 1145 1153 10.1200/JCO.2009.22.4725 1:CAS:528:DC%2BC3cXktF2ltLk%3D 10.1200/JCO.2009.22. 4725 20100965
33. Font A, Taron M, Gago JL, Costa C, Sánchez JJ, Carrato C, Mora M, Celiz P, Perez L, Rodríguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R (2010) BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. doi: 10.1093/annonc/mdq333
34. JE Quinn CR James GE Stewart JM Mulligan P White GK Chang PB Mullan PG Johnston RH Wilson DP Harkin 2007 BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clin Cancer Res 13 7413 7420 10.1158/1078-0432.CCR-07-1083 1:CAS:528:DC%2BD2sXhsVCktr3J 10.1158/1078-0432.CCR-07-1083 18094425
35. M Taron R Rosell E Felip P Mendez J Souglakos MS Ronco C Queralt J Majo JM Sanchez JJ Sanchez J Maestre 2004 BRCA1 mRNA expression as an indicator of chemoresistance in lung cancer Hum Mol Genet 13 2443 2449 10.1093/hmg/ddh260 1:CAS:528:DC%2BD2cXnvVOktLo%3D 10.1093/hmg/ddh260 15317748 (Pubitemid 39377848)
36. SM Aris NP Farrell 2009 Towards antitumor active trans-platinum compounds Eur J Inorg Chem 2009 1293 1302 10.1002/ejic.200801118 10.1002/ejic.200801118 20161688